Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000

European Journal of Epidemiology

Volumn 21, Issue 5, 2006, Pages 389-396

  Deuffic Burban, Sylvie ^a   Costagliola, Dominique ^b  

^a IESEG School of Management   (France)

^b INSERM   (France)

Author keywords

Back calculation method; French Hospital Database on HIV; HIV prevalence; Pre AIDS mortality

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; FRANCE; HEMOPHILIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORTALITY; POPULATION MODEL; POPULATION RESEARCH; PREVALENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE TRANSMISSION, VERTICAL; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 33745876564     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-006-9003-3     Document Type: Article

References (22)

1. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130.
2. Louie J, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Fransisco, 1994-1998. J Infect Dis 2002; 186: 1023-1027.
3. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663-1671.
4. Deuffic S, Costagliola D. Is the AIDS incubation time changing? A backcalculation approach. Stat Med 1999; 18: 1031-1047.
5. Deuffic-Burban S, Wong JB, Valleron A-J, Costagliola D, Delfraissy JF, Poynard T. Comparing the Public Health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319-326.
6. Brookmeyer R, Gail M. The minimum size of the AIDS epidemic in the United States. Lancet 1986; ii: 1320-1322.
7. Brookmeyer R, Gail MH. A method for obtaining short term projections and lower bounds on the size of the AIDS epidemics. J Am Stat Assoc 1988; 83: 301-308.
8. Tassie JM, Grabar S, Lancar R, Deloumeaux J, Bentata M, Costagliola D. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. J Acquir Immune Defic Syndr 2002; 30: 81-87.
9. Brookmeyer R, Liao J. The analysis of delays in disease reporting: methods and results for the acquired immunodeficiency syndrome. Am J Epidemiol 1990; 132: 355-365.
10. Bernillon P, Lièvre L, Pillonel J, Laporte A, Costagliola D. Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficience Humaine. Int J Epidemiol 2000; 29: 168-174.
11. Rapport Delfraissy. Prise en charge des personnes infectées par le VIH. Paris République Française: Ministère de la Santé et de la Protection Sociale, 2002.
12. Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D. Le sexe et le groupe de transmission de patients infectés par le VIH influencent-ils l'initiation d'un traitement anti-retroviral hautement actif et la réponse clinico-biologique sous traitement? In: 23ème réunion interdisciplinaire de chimiothérapie anti-infectieuse (RICAI); 4-5 Décembre, Paris, France; 2003; 55/ 10c.
13. Lewden C, Raffi F, Chene G, Sobel A, Leport C. Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. J Acquir Immune Defic Syndr 2001; 26: 480-482.
14. Lewden C. APROCO-COPILOTE Study Group, Aquitaine Cohort Study Group. Responders to antiretroviral treatment over 500 CD4/mm3 reach same mortality rates as general population: APROCO and Aquitaine cohorts, France. In: Proceedings of the 10th European AIDS Conference/EACS; Nov 17-20, 2005; Dublin, Ireland [PE18.4/8].
15. Becker NG, Marschner IC. A method for estimating the age-specific relative risk on HIV infection from AIDS incidence data. Biometrika 1993; 80: 165-178.
16. Burnham K, Anderson D. Model Selection and Inference: A Practical Information - Theoretical Approach. New-York: Springel-Verlag, 1998.
17. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Amer Statist 1983; 37: 36-48.
18. Schwartländer B, Stanecki KA, Brown T, et al. Country-specific estimates and models of HIV and AIDS: methods and limitations. AIDS 1999; 13: 2445-2458.
19. The UNAIDS Reference Group on Estimates MaP. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommandations of the UNAIDS Reference Group on Estimates, Modelling and Projections. AIDS 2002; 16: W1-W14.
20. Walker N, Stanecki KA, Brown T, et al. Methods and procedures for estimating HIV/AIDS and its impact: the UNAIDS/WHO estimates for the end of 2001. AIDS 2003; 17: 2215-2225.
21. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280: 1497-1503.
22. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362: 1267-1274.